FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149783480> ?p ?o ?g. }

• W2149783480 endingPage "236" @default.
• W2149783480 startingPage "228" @default.
• W2149783480 abstract "IntroductionBone metastases from non-small cell lung cancer (NSCLC) are associated with skeletal-related events (SREs) and elevated levels of N-telopeptide of type I collagen (NTX) in some patients. Zoledronic acid (ZOL) reduces SRE risk and NTX levels.MethodsTo assess effects of baseline variables, including NTX levels (normal = NTX < 64 nmol/mmol creatinine; high = NTX ≥ 64 nmol/mmol creatinine), on treatment effects in NSCLC patients, a retrospective analysis was performed in NSCLC patients with bone metastases (N = 382) treated with ZOL or placebo every 3 weeks in a 21-month randomized clinical trial in patients with NSCLC or other solid tumors. Cox proportional hazards models assessed relative risks (RRs) of SREs, bone lesion progression, and death. Multivariate models analyzed covariate effects on survival.ResultsFor both placebo- and ZOL-treated patients, high baseline NTX correlated with increased SRE risk (p = 0.068 and 0.012, respectively). Although high versus normal baseline NTX correlated with more than twofold increased risks of bone lesion progression and death in the placebo group (p = 0.039 and 0.001, respectively), correlations were weaker in the ZOL group (RR = 1.38; p = 0.0186 and RR = 1.27; p = 0.142, respectively), suggesting an interaction effect of ZOL and baseline NTX. Among patients with high baseline NTX, ZOL significantly reduced the RR of death by 35% versus placebo (p = 0.024). Per multivariate analysis, ZOL treatment (p = 0.005), higher lymphocyte count (p = 0.011), performance status 0 to 1 (p = 0.012), and absence of narcotic use (p = 0.016) correlated with improved survival.ConclusionsThis retrospective analysis revealed statistically significant correlations between ZOL and increased survival versus placebo in NSCLC patients and high baseline NTX levels. Bone metastases from non-small cell lung cancer (NSCLC) are associated with skeletal-related events (SREs) and elevated levels of N-telopeptide of type I collagen (NTX) in some patients. Zoledronic acid (ZOL) reduces SRE risk and NTX levels. To assess effects of baseline variables, including NTX levels (normal = NTX < 64 nmol/mmol creatinine; high = NTX ≥ 64 nmol/mmol creatinine), on treatment effects in NSCLC patients, a retrospective analysis was performed in NSCLC patients with bone metastases (N = 382) treated with ZOL or placebo every 3 weeks in a 21-month randomized clinical trial in patients with NSCLC or other solid tumors. Cox proportional hazards models assessed relative risks (RRs) of SREs, bone lesion progression, and death. Multivariate models analyzed covariate effects on survival. For both placebo- and ZOL-treated patients, high baseline NTX correlated with increased SRE risk (p = 0.068 and 0.012, respectively). Although high versus normal baseline NTX correlated with more than twofold increased risks of bone lesion progression and death in the placebo group (p = 0.039 and 0.001, respectively), correlations were weaker in the ZOL group (RR = 1.38; p = 0.0186 and RR = 1.27; p = 0.142, respectively), suggesting an interaction effect of ZOL and baseline NTX. Among patients with high baseline NTX, ZOL significantly reduced the RR of death by 35% versus placebo (p = 0.024). Per multivariate analysis, ZOL treatment (p = 0.005), higher lymphocyte count (p = 0.011), performance status 0 to 1 (p = 0.012), and absence of narcotic use (p = 0.016) correlated with improved survival. This retrospective analysis revealed statistically significant correlations between ZOL and increased survival versus placebo in NSCLC patients and high baseline NTX levels." @default.
• W2149783480 created "2016-06-24" @default.
• W2149783480 creator A5017925159 @default.
• W2149783480 creator A5043397424 @default.
• W2149783480 creator A5047198395 @default.
• W2149783480 creator A5051980635 @default.
• W2149783480 creator A5054553011 @default.
• W2149783480 creator A5056951639 @default.
• W2149783480 creator A5083726052 @default.
• W2149783480 creator A5090256464 @default.
• W2149783480 date "2008-03-01" @default.
• W2149783480 modified "2023-10-10" @default.
• W2149783480 title "Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity" @default.
• W2149783480 cites W1932993947 @default.
• W2149783480 cites W1952946804 @default.
• W2149783480 cites W1965734230 @default.
• W2149783480 cites W1969207876 @default.
• W2149783480 cites W1978686242 @default.
• W2149783480 cites W1985172769 @default.
• W2149783480 cites W1996589664 @default.
• W2149783480 cites W2006495870 @default.
• W2149783480 cites W2010808964 @default.
• W2149783480 cites W2018657706 @default.
• W2149783480 cites W2028243830 @default.
• W2149783480 cites W2036616071 @default.
• W2149783480 cites W2038995854 @default.
• W2149783480 cites W2047924366 @default.
• W2149783480 cites W2052595539 @default.
• W2149783480 cites W2072693298 @default.
• W2149783480 cites W2079742505 @default.
• W2149783480 cites W2081947987 @default.
• W2149783480 cites W2104923745 @default.
• W2149783480 cites W2109333569 @default.
• W2149783480 cites W2115962082 @default.
• W2149783480 cites W2123171945 @default.
• W2149783480 cites W2125014991 @default.
• W2149783480 cites W2137083298 @default.
• W2149783480 cites W2161962336 @default.
• W2149783480 cites W2162827359 @default.
• W2149783480 cites W2320853964 @default.
• W2149783480 cites W2339199522 @default.
• W2149783480 cites W2524796523 @default.
• W2149783480 cites W4253318136 @default.
• W2149783480 doi "https://doi.org/10.1097/jto.0b013e3181651c0e" @default.
• W2149783480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18317064" @default.
• W2149783480 hasPublicationYear "2008" @default.
• W2149783480 type Work @default.
• W2149783480 sameAs 2149783480 @default.
• W2149783480 citedByCount "137" @default.
• W2149783480 countsByYear W21497834802012 @default.
• W2149783480 countsByYear W21497834802013 @default.
• W2149783480 countsByYear W21497834802014 @default.
• W2149783480 countsByYear W21497834802015 @default.
• W2149783480 countsByYear W21497834802016 @default.
• W2149783480 countsByYear W21497834802017 @default.
• W2149783480 countsByYear W21497834802018 @default.
• W2149783480 countsByYear W21497834802019 @default.
• W2149783480 countsByYear W21497834802020 @default.
• W2149783480 countsByYear W21497834802021 @default.
• W2149783480 countsByYear W21497834802022 @default.
• W2149783480 countsByYear W21497834802023 @default.
• W2149783480 crossrefType "journal-article" @default.
• W2149783480 hasAuthorship W2149783480A5017925159 @default.
• W2149783480 hasAuthorship W2149783480A5043397424 @default.
• W2149783480 hasAuthorship W2149783480A5047198395 @default.
• W2149783480 hasAuthorship W2149783480A5051980635 @default.
• W2149783480 hasAuthorship W2149783480A5054553011 @default.
• W2149783480 hasAuthorship W2149783480A5056951639 @default.
• W2149783480 hasAuthorship W2149783480A5083726052 @default.
• W2149783480 hasAuthorship W2149783480A5090256464 @default.
• W2149783480 hasBestOaLocation W21497834801 @default.
• W2149783480 hasConcept C121608353 @default.
• W2149783480 hasConcept C126322002 @default.
• W2149783480 hasConcept C141071460 @default.
• W2149783480 hasConcept C142724271 @default.
• W2149783480 hasConcept C143998085 @default.
• W2149783480 hasConcept C204787440 @default.
• W2149783480 hasConcept C27081682 @default.
• W2149783480 hasConcept C2776256026 @default.
• W2149783480 hasConcept C2776326535 @default.
• W2149783480 hasConcept C2777783956 @default.
• W2149783480 hasConcept C2780192828 @default.
• W2149783480 hasConcept C2780306776 @default.
• W2149783480 hasConcept C44249647 @default.
• W2149783480 hasConcept C71924100 @default.
• W2149783480 hasConcept C82789193 @default.
• W2149783480 hasConcept C90924648 @default.
• W2149783480 hasConceptScore W2149783480C121608353 @default.
• W2149783480 hasConceptScore W2149783480C126322002 @default.
• W2149783480 hasConceptScore W2149783480C141071460 @default.
• W2149783480 hasConceptScore W2149783480C142724271 @default.
• W2149783480 hasConceptScore W2149783480C143998085 @default.
• W2149783480 hasConceptScore W2149783480C204787440 @default.
• W2149783480 hasConceptScore W2149783480C27081682 @default.
• W2149783480 hasConceptScore W2149783480C2776256026 @default.
• W2149783480 hasConceptScore W2149783480C2776326535 @default.
• W2149783480 hasConceptScore W2149783480C2777783956 @default.
• W2149783480 hasConceptScore W2149783480C2780192828 @default.

• next